blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

Latvia joins the Federated Register
Click here for more information on the Federated Register.

2025-04-16

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3306310

EP3306310 - METHOD FOR QUANTIFYING MONOCLONAL ANTIBODY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  11.06.2021
Database last updated on 05.05.2025
FormerThe patent has been granted
Status updated on  03.07.2020
FormerGrant of patent is intended
Status updated on  02.01.2020
FormerRequest for examination was made
Status updated on  09.03.2018
FormerThe international publication has been made
Status updated on  09.12.2016
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 16.10.2024  [2024/42]
Applicant(s)For all designated states
Shimadzu Corporation
1, Nishinokyo-Kuwabara-cho
Nakagyo-ku
Kyoto-shi, Kyoto 604-8511 / JP
For all designated states
National Cancer Center
1-1 Tsukiji 5-chome
Chuo-ku
Tokyo 104-0045 / JP
[2018/15]
Inventor(s)01 / SHIMADA Takashi
c/o SHIMADZU CORPORATION
1 Nishinokyo-Kuwabara-cho
Nakagyo-ku
Kyoto-shi Kyoto 604-8511 / JP
02 / IWAMOTO Noriko
c/o SHIMADZU CORPORATION
1 Nishinokyo-Kuwabara-cho
Nakagyo-ku
Kyoto-shi Kyoto 604-8511 / JP
03 / HAMADA Akinobu
c/o National Cancer Center
1-1 Tsukiji 5-chome
Chuo-ku
Tokyo 104-0045 / JP
 [2018/15]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[2020/32]
Former [2018/15]Webster, Jeremy Mark
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
Application number, filing date15894149.201.06.2015
[2018/15]
WO2015JP65806
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016194114
Date:08.12.2016
Language:JA
[2016/49]
Type: A1 Application with search report 
No.:EP3306310
Date:11.04.2018
Language:EN
[2018/15]
Type: B1 Patent specification 
No.:EP3306310
Date:05.08.2020
Language:EN
[2020/32]
Search report(s)International search report - published on:JP08.12.2016
(Supplementary) European search report - dispatched on:EP23.10.2018
ClassificationIPC:G01N27/62, C12Q1/37
[2018/15]
CPC:
G01N27/62 (EP,US); C12Q1/37 (US); C12Y304/21001 (EP,US);
C12Y304/21004 (EP,US); G01N30/7233 (US); G01N33/94 (US);
G01N2333/7158 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/15]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:VERFAHREN ZUR QUANTIFIZIERUNG VON MONOKLONALEN ANTIKÖRPERN[2018/15]
English:METHOD FOR QUANTIFYING MONOCLONAL ANTIBODY[2018/15]
French:PROCÉDÉ DE QUANTIFICATION D'ANTICORPS MONOCLONAL[2018/15]
Entry into regional phase19.12.2017Translation filed 
19.12.2017National basic fee paid 
19.12.2017Search fee paid 
19.12.2017Designation fee(s) paid 
19.12.2017Examination fee paid 
Examination procedure19.12.2017Examination requested  [2018/15]
19.12.2017Date on which the examining division has become responsible
09.05.2018Amendment by applicant (claims and/or description)
03.01.2020Communication of intention to grant the patent
30.04.2020Fee for grant paid
30.04.2020Fee for publishing/printing paid
30.04.2020Receipt of the translation of the claim(s)
Opposition(s)07.05.2021No opposition filed within time limit [2021/28]
Fees paidRenewal fee
19.12.2017Renewal fee patent year 03
25.06.2018Renewal fee patent year 04
21.06.2019Renewal fee patent year 05
29.06.2020Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU01.06.2015
AL05.08.2020
AT05.08.2020
CY05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
IT05.08.2020
LT05.08.2020
LV05.08.2020
MC05.08.2020
MK05.08.2020
MT05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SI05.08.2020
SK05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
[2024/42]
Former [2024/22]HU01.06.2015
AL05.08.2020
AT05.08.2020
CY05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
IT05.08.2020
LT05.08.2020
LV05.08.2020
MC05.08.2020
MK05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SI05.08.2020
SK05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2023/33]HU01.06.2015
AL05.08.2020
AT05.08.2020
CY05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
IT05.08.2020
LT05.08.2020
LV05.08.2020
MC05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SI05.08.2020
SK05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2023/30]AL05.08.2020
AT05.08.2020
CY05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
IT05.08.2020
LT05.08.2020
LV05.08.2020
MC05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SI05.08.2020
SK05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2022/08]AL05.08.2020
AT05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
IT05.08.2020
LT05.08.2020
LV05.08.2020
MC05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SI05.08.2020
SK05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/36]AL05.08.2020
AT05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
IT05.08.2020
LT05.08.2020
LV05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SI05.08.2020
SK05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/34]AL05.08.2020
AT05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
IT05.08.2020
LT05.08.2020
LV05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SK05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/28]AL05.08.2020
AT05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SK05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/25]AL05.08.2020
AT05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/22]AT05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/21]AT05.08.2020
DK05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
NL05.08.2020
PL05.08.2020
RS05.08.2020
SE05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/12]AT05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
NL05.08.2020
PL05.08.2020
RS05.08.2020
SE05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/10]AT05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
PL05.08.2020
RS05.08.2020
SE05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/09]AT05.08.2020
ES05.08.2020
FI05.08.2020
LT05.08.2020
SE05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
PT07.12.2020
Former [2021/08]ES05.08.2020
FI05.08.2020
LT05.08.2020
SE05.08.2020
BG05.11.2020
NO05.11.2020
PT07.12.2020
Former [2021/07]FI05.08.2020
LT05.08.2020
NO05.11.2020
Documents cited:Search[XI]WO2015033479  (SHIMADZU CORP [JP]) [X] 1-3,5,6,8,9 * fig 1; abs; claims 1, 7, 11, 13; par [0007], [0030], [0042]; examples * [I] 1-9;
 [I]  - NORIKO IWAMOTO ET AL, "Selective detection of complementarity-determining regions of monoclonal antibody by limiting protease access to the substrate: nano-surface and molecular-orientation limited proteolysis", ANALYST,, vol. 139, no. 3, doi:10.1039/C3AN02104A, ISSN 1364-5528, (20140207), pages 576 - 580, (20131129), XP002782006 [I] 1-9 * figure 1 *

DOI:   http://dx.doi.org/10.1039/c3an02104a
International search[Y]JP2014510267  (Leiden University Medical Center) [Y] 1-9 * , paragraphs [0055], [0064] to [0065], [0074] to [0076] & US 2013/0316463 A1 & WO 2012/107572 A1 & EP 2673065 A1 & CA 2826337 A1 & CN 103458983 A & KR 10-2014-0114276 A *;
 [Y]WO2015033479  (SHIMADZU CORP [JP]) [Y] 1-9 * , paragraphs [0035] to [0089], [0109] to [0126]; fig. 1 to 3, 7 to 12 & TW 201510222 A *;
 [A]  - CHOEI KOBATAKE et al., "Pharmacological and clinical profile of mogamulizumab (POTELIGEO Injection", Folia pharmacologica Japonica, (20130201), vol. 141, no. 2, pages 100 - 105, XP055333552 [A] 3-4, 7
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.